Home
/
China
/
Shanghai Fourier Intelligent Technology Co., Ltd.

Fourier

Fourier develops advanced robotics for medical rehabilitation and humanoid robots, serving 2000+ hospitals in 40+ countries with intelligent, dexterous robots.
Legal Name
This is some text inside of a div block.
Founded
Jul 2015
Company Type
Private
Company Size
11 - 50
Address
Room 203, 204, 205, 206, Building 8, No. 2388 Xiupu Road, Kangqiao Town, Pudong New District, Shanghai
China
No items found.
Presence in Countries
No items found.
Founding Country
China
IPO Date
Stock Symbol
Leadership
-
Astralis Awards
-

Intro

Founded by Alex Gu in 2015, Fourier Robotics initially focused on rehabilitation robotics, developing exoskeletons and rehab platforms used worldwide in over 2000 hospitals across 40+ countries. The company expanded into humanoid robots, launching the GR-1 in 2023, the first mass-produced humanoid robot in the industry, followed by the upgraded GR-2 in 2024. Fourier integrates embodied AI, robotics hardware, and software platforms to enhance rehabilitation and general-purpose robotics. A key achievement is the GR-1 humanoid robot, capable of bipedal walking, real-time mapping, navigation, and obstacle avoidance with human-like precision, marking a leap in embodied AI and robotics production.

Robots

  • GR-1 Humanoid Robot: A 1.65-meter tall robot with full-body balance and agility, capable of bipedal walking and complex navigation, launched in 2023 and mass-produced for research and development.
  • GR-2 Humanoid Robot: An upgraded 1.75-meter model with 53 degrees of freedom, enhanced load capacity, detachable battery, and improved software, unveiled in 2024.
  • Fourier X1 Exoskeleton: The first lower-limb exoskeleton for commercial use in mainland China, launched in 2017 to assist mobility and rehabilitation.

Specialism

  • Development of rehabilitation robotics including exoskeletons and virtual reality platforms for physical therapy.
  • Embodied AI integration enabling humanoid robots with real-time perception, navigation, and manipulation.
  • Open robotics platform (EXOPS) for exoskeleton development and customization.
  • Mass production capabilities for humanoid robots with advanced sensor fusion and AI.
  • Biomechanics analysis and rehab platforms integrating robotics and VR (MetaMotus™ Galileo).

Business Viability

  • Over 2000 installations in hospitals and rehab centers globally, demonstrating strong market penetration.
  • Backed by major investors including IDG Capital and Saudi Aramco’s Prosperity7 Ventures, with over $80 million raised.
  • Strategic acquisition of Zhuhai RHK Healthcare in 2020 expanded service network and data resources.
  • Government interest highlighted by Chinese leader Xi Jinping’s visit and engagement with the company’s humanoid robot in 2023.
  • Continuous innovation with new product launches and upgrades, aiming for thousands of humanoid robot deliveries in 2024.
  • Strong global footprint with offices and operations in China, Singapore, and other regions.